Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganirelix

Drug Profile

Ganirelix

Alternative Names: Antagon; Ganirelix acetate; Ganirest; ORG 37462; Orgalutran; RS 26306

Latest Information Update: 18 Nov 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Merck & Co
  • Class Antihormones; Infertility therapies; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jan 2009 Launched for Female infertility in Japan (SC)
  • 21 Jul 2001 A study has been added to the adverse events and Women's Health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top